通过血液生物标志物和临床特征预测早期阿尔茨海默病
Muaath Ebrahim AlMansoori1, Sherlyn Jemimah1, Ferial Abuhantash1
1Department of Biomedical Engineering, Khalifa University, P.O. Box: 127788, Abu Dhabi, United Arab Emirates.
Scientific reports
|March 13, 2024
概括
这项研究使用机器学习来使用血液数据检测阿尔茨海默病 (AD). 遗传生物标志物对早期阿尔茨海默氏症诊断和了解疾病充满希望.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 计算生物学 计算生物学
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,没有治愈.
- 准确和早期诊断阿尔茨海默病仍然是一个重大的临床挑战.
- 非侵入性诊断方法对于有效的AD管理至关重要.
研究的目的:
- 开发和验证用于AD检测的可解释机器学习模型.
- 通过使用多模式数据,识别用于早期AD诊断的新生物标志物.
- 通过数据驱动的洞察力,增强对AD病原学的理解.
主要方法:
- 利用了血液基因表达,单核酸多态 (SNP) 和来自阿尔茨海默氏病神经成像计划 (ADNI) 队列的临床数据.
- 使用的支持矢量机器 (SVM) 分类器与相互信息 (MI) 进行特征选择.
- 应用了夏普利添加剂解释 (SHAP) 来实现模型解释性和生物标志物识别.
主要成果:
- 综合模型 (基因表达,SNP,临床数据) 实现了高精度 (0.95) 和AUC (0.94).
- 基因表达和SNP数据单独显示出良好的表现 (AUC分别为0.65和0.63).
- 确定了与轴突髓化和突触囊泡膜形成相关的潜在AD生物标志物.
结论:
- 集成多模式数据的可解释AI模型显示,对准确的AD诊断有很大的希望.
- 基于基因的生物标志物为早期AD检测和治疗点发现提供了潜在的途径.
- 这种方法为AD机制提供了有价值的见解,并支持开发非侵入性诊断工具.
相关概念视频
01:26Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481
01:30Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
01:22Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188